Sandoz Accuses China of Antibiotic 'Dumping,' Citing Strategic Health Risks

Swiss generics powerhouse Sandoz is no longer pulling punches. The Basel-based giant has officially lodged a draft complaint with the European Commission, accusing Chinese manufacturers of 'dumping' low-priced antibiotics into the Western market. This isn't just a trade dispute; it is a battle for the survival of European medicine. Sandoz alleges that Chinese suppliers benefit from massive state subsidies, allowing them to slash prices to levels that distort competition and drive domestic producers to the brink of extinction. The primary target is penicillin—the backbone of amoxicillin—which has seen its market value eroded by what Sandoz describes as predatory pricing. While consumers might enjoy lower costs today, the long-term price of this dependency could be catastrophic. CEO Richard Saynor warns that European decision-makers have been 'too hesitant for too long,' allowing a vital industry to be hollowed out by foreign interests.

A staggering 90% of the world’s antibiotic active substances are now manufactured outside of Europe, with the lion's share concentrated in China. This overwhelming dominance has created a 'critical strategic vulnerability' that threatens the very fabric of public health. When nine out of ten life-saving ingredients originate from a single geopolitical rival, the risk of supply chain blackmail or sudden shortages becomes a matter of national security. Sandoz CEO Richard Saynor argues that antibiotics are being 'systematically undervalued' by a system that prioritizes the lowest possible price over the reliability of the supply. This race to the bottom has decimated the European manufacturing base, leaving the continent exposed. In contrast to other high-tech sectors, the pharmaceutical supply chain has been allowed to drift into a state of dangerous dependency, a fact that Saynor insists politicians can no longer ignore.

Against this tide of cheap imports, Sandoz is fighting to protect the Kundl plant in Austria—the last remaining large-scale antibiotics facility on the continent. As the site celebrates its 80th anniversary this week, it stands as a lonely sentinel of European industrial capability. The survival of Kundl is not just a matter of corporate pride; it is the final line of defense against a total Chinese monopoly on penicillin production. Maintaining such a facility in a high-cost environment like Europe is an uphill battle when faced with subsidized competition. Sandoz is calling for a radical rethink of how essential medicines are procured. Instead of rewarding the cheapest bidder, the company argues that procurement should factor in 'crisis preparedness' and regional stability. Without immediate intervention, the institutional knowledge and infrastructure of eight decades could vanish, leaving Europe entirely at the mercy of global trade winds.

The tide may finally be turning as European leaders begin to wake up to the risks of pharmaceutical offshoring. The 'Alpbach Communiqué' has already set an ambitious target: at least 30% of European medical supplies must come from domestic producers. Furthermore, the proposed Critical Medicines Act represents a significant step toward securing the supply chain, though Sandoz warns that implementation details remain dangerously vague. The Swiss multinational is urging Europe to look toward India as a model; the South Asian giant has already implemented minimum import prices to shield its own antibiotic industry from Chinese dumping. For Switzerland and its neighbors, the choice is clear: either invest in health sovereignty now or pay a much higher price during the next global health crisis. The era of treating life-saving medicine as a mere commodity is over; the era of strategic healthcare has begun.